Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR)

被引:22
作者
Gudbjoernsdottir, S. [2 ]
Eeg-Olofsson, K. [2 ]
Cederholm, J. [3 ]
Zethelius, B. [4 ]
Eliasson, B. [2 ]
Nilsson, P. M. [1 ]
机构
[1] Lund Univ, Malmo Univ Hosp, Dept Clin Sci, S-20502 Malmo, Sweden
[2] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Med, Gothenburg, Sweden
[3] Uppsala Univ, Dept Publ Hlth & Caring Sci Family Med & Clin Epi, Uppsala, Sweden
[4] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden
关键词
coronary heart disease; diabetes mellitus; hyperlipidaemia; hypertension; secondary prevention; BLOOD-GLUCOSE CONTROL; MYOCARDIAL-INFARCTION; PRIMARY PREVENTION; CARDIOVASCULAR-DISEASES; CONTROLLED-TRIAL; ARTERY-DISEASE; EUROASPIRE-II; EURO HEART; MORTALITY; MELLITUS;
D O I
10.1111/j.1464-5491.2008.02633.x
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Patients with Type 2 diabetes and coronary heart disease (CHD) are infrequently treated to risk factor targets in current guidelines. We aimed to examine risk factor management and control levels in a large sample of patients with Type 2 diabetes with CHD. This was an observational study of 1612 patients with first incidence of CHD before 2002, and of 4570 patients with first incidence of CHD before 2005, from the Swedish National Diabetes Register (NDR). In patients with CHD 1-2 years before follow-up, the achievement of cardiovascular risk factor targets (follow-up 2002/follow-up 2005) was: HbA(1c) < 7%, 47%/54% (P < 0.01); blood pressure <= 130/80 mmHg, 31%/40% (P < 0.001); total cholesterol < 4.5 mmol/l, 47%/60% (P < 0.001); and low-density lipoprotein-cholesterol < 2.5 mmol/l, 49%/65% (P < 0.001). Use of medication: antihypertensives, 90%/94% (P < 0.01); lipid-lowering drugs, 75%/86% (P < 0.001); and aspirin, 85%/89% (P < 0.05). A high prevalence of adverse lifestyle characteristics prevailed (2002/2005): overweight [body mass index (BMI) >= 25 kg/m(2)], 86%/85%; obesity (BMI >= 30 kg/m(2)), 41%/42%; smokers in age group < 65 years, 16-23%/18-19%; as well as waist circumference >= 102 cm (men) or >= 88 cm (women), 68% in 2005. Patients with a combination of Type 2 diabetes and CHD showed an increased use of lipid-lowering drugs over time, corresponding to improving blood lipid levels. A discrepancy existed between the prevalent use of antihypertensive drugs and the low proportion reaching blood pressure targets. Regretfully, a high prevalence of adverse lifestyle characteristics prevailed. Evidence-based therapy with professional lifestyle intervention and drugs seems urgent for improved quality of secondary prevention in these patients. Diabet. Med. 26, 53-60 (2009).
引用
收藏
页码:53 / 60
页数:8
相关论文
共 30 条
[1]
Management of coronary artery disease in patients with and without diabetes mellitus.: Acute management reasonable but secondary prevention unacceptably poor:: A report from the Euro Heart Survey on Diabetes and the heart [J].
Anselmino, Matteo ;
Bartnik, Malgorzata ;
Malmberg, Klas ;
Ryden, Lars .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2007, 14 (01) :28-36
[2]
Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study [J].
Booth, Gillian L. ;
Kapral, Moira K. ;
Fung, Kinwah ;
Tu, Jack V. .
LANCET, 2006, 368 (9529) :29-36
[3]
Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association [J].
Buse, John B. ;
Ginsberg, Henry N. ;
Bakris, George L. ;
Clark, Nathaniel G. ;
Costa, Fernando ;
Eckel, Robert ;
Fonseca, Vivian ;
Gerstein, Hertzel C. ;
Grundy, Scott ;
Nesto, Richard W. ;
Pignone, Michael P. ;
Plutzky, Jorge ;
Porte, Daniel ;
Redberg, Rita ;
Stitzel, Kimberly F. ;
Stone, Neil J. .
CIRCULATION, 2007, 115 (01) :114-126
[4]
Microalbuminuria and risk factors in type 1 and type 2 diabetic patients [J].
Cederholm, J ;
Eliasson, B ;
Nilsson, PM ;
Weiss, L ;
Gudbjörnsdottir, S .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 67 (03) :258-266
[5]
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[6]
The gap between guidelines and reality:: Type 2 diabetes in a national diabetes register 1996-2003 [J].
Eliasson, B ;
Cederholm, J ;
Nilsson, P ;
Gudbjörnsdóttir, S .
DIABETIC MEDICINE, 2005, 22 (10) :1420-1426
[7]
HYPERTRIGLYCERIDEMIA AS A RISK FACTOR OF CORONARY HEART-DISEASE MORTALITY IN SUBJECTS WITH IMPAIRED GLUCOSE-TOLERANCE OR DIABETES - RESULTS FROM THE 11-YEAR FOLLOW-UP OF THE PARIS PROSPECTIVE-STUDY [J].
FONTBONNE, A ;
ESCHWEGE, E ;
CAMBIEN, F ;
RICHARD, JL ;
DUCIMETIERE, P ;
THIBULT, N ;
WARNET, JM ;
CLAUDE, JR ;
ROSSELIN, GE .
DIABETOLOGIA, 1989, 32 (05) :300-304
[8]
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy:: the LIFE study [J].
Fossum, E. ;
Gleim, G. W. ;
Kjeldsen, S. E. ;
Kizer, J. R. ;
Julius, S. ;
Devereux, R. B. ;
Brady, W. E. ;
Hille, D. A. ;
Lyle, P. A. ;
Dahlof, B. .
JOURNAL OF INTERNAL MEDICINE, 2007, 262 (04) :439-448
[9]
Effect of a multifactorial intervention on mortality in type 2 diabetes [J].
Gaede, Peter ;
Lund-Andersen, Henrik ;
Parving, Hans-Henrik ;
Pedersen, Oluf .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :580-591
[10]
The national diabetes register in Sweden -: An implementation of the St. Vincent declaration for quality improvement in diabetes care [J].
Gudbjörnsdottir, S ;
Cederholm, J ;
Nilsson, PM ;
Eliasson, B .
DIABETES CARE, 2003, 26 (04) :1270-1276